Researchers with the James P. Allison Institute™ at The University of Texas MD Anderson Cancer Center have discovered a new ...

For prostate cancer patients with low-volume tumors and metastasis, the median overall survival was 37.13 months. Prostate cancer patients with metastatic disease and low-volume primary tumors appear ...

Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with ...

These results correspond to an 80% reduction in the risk of death among patients surviving beyond five years.

U.S. study supports findings from a global trial using an external control arm ...

Dr Hannah McManus looks ahead to the release of new data from phase 3 clinical trials that will inform multidisciplinary management.

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...

When prostate cancer spreads beyond the prostate gland to other parts of the body, it becomes what medical professionals call metastatic prostate cancer. This advanced form of the disease represents a ...

Prostate-specific membrane antigen (PSMA)-PET/CT imaging identified metastatic prostate cancer in almost half of high-risk cases missed by conventional imaging, a retrospective analysis showed.

A new blood test could help doctors identify whether a treatment for advanced prostate cancer is failing weeks earlier than ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical ...

Novartis announces new PSMAddition data shows 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer: Basel Tuesday, May 19, 2026, 16:00 H ...